Global Presence Aton Pharma's products are sold in over 30 countries, indicating a strong international footprint that can be leveraged for expanding distribution channels and exploring new markets globally.
Specialized Focus With a focus on ophthalmology, orphan diseases, and acute care, Aton presents targeted opportunities for partnerships and sales in niche healthcare segments where innovative treatments are in demand.
Emerging Revenue Having a revenue range of 25 to 50 million dollars, Aton is a growth-oriented company that may be receptive to new product introductions, licensing deals, or joint ventures to accelerate its market share.
Acquisition Backdrop Since its acquisition from Merck & Co. by Princeton Pharma Holdings, Aton has been positioned as a flexible and potentially collaborative partner for customized pharmaceutical solutions in specialized therapeutic areas.
Industry Competition Operating alongside large-scale competitors like Hikma, Aurobindo, and others, there are opportunities for tailored value propositions that highlight innovation, niche specialization, and personalized service to gain a competitive edge.
$1B$10B
$250M$500M
$1B$10B
$1B$10B
$1B$10B
$1B$10B
$25M$50M| Aton Pharma, Inc. Email Formats | Percentage |
| FLast@atonrx.com | 30% |
| First.Last@atonrx.com | 20% |
| FLast@atonrx.com | 30% |
| First.Last@atonrx.com | 20% |
Pharmaceutical ManufacturingNew Jersey, United States2-10 Employees
Aton is a diversified specialty pharmaceutical company with product sales in over 30 countries. The company was acquired from Merck & Co. Inc. by Princeton Pharma Holdings LLC in October of 2006. The company focuses on unique products in opthalmology, orphan diseases and acute care.
Company Overview
Funding & FinancialsAton Pharma, Inc.'s revenue is estimated to be in the range of $25M$50M
Funding & FinancialsAton Pharma, Inc.'s revenue is estimated to be in the range of $25M$50M
1-888-653-2347 
support@leadiq.com